A 38-year-old woman from rural Maharashtra presents with a 6-month history of polyuria, polydipsia, and a 4 kg weight loss. She reports no prior diabetes in her family. On examination, she appears lean (BMI 21 kg/m²) with no acanthosis nigricans. Fasting blood glucose is 156 mg/dL, and HbA1c is 8.2%. C-peptide level is 0.3 ng/mL (normal 0.8–3.1). Anti-GAD and anti-IA2 antibodies are positive. What is the most likely pathological mechanism underlying her diabetes?

Explanation

## Diagnosis: Latent Autoimmune Diabetes in Adults (LADA) ### Clinical Presentation This patient presents with classic features of LADA: - Age >30 years with gradual onset (6 months) - Lean body habitus (BMI 21) — rules out typical Type 2 DM - Absence of acanthosis nigricans — argues against insulin resistance - Low C-peptide (0.3 ng/mL) — indicates severely reduced β-cell function - **Positive anti-GAD and anti-IA2 antibodies** — hallmark of autoimmune destruction ### Pathological Mechanism **Key Point:** LADA is characterized by **autoimmune-mediated destruction of pancreatic β-cells**, identical to Type 1 DM but with a slower progression (often called "Type 1.5 DM"). The positive autoantibodies (anti-GAD65, anti-IA2) indicate: 1. T-cell mediated attack on β-cell autoantigens 2. Gradual loss of β-cell mass and function 3. Progressive decline in insulin secretion (reflected by low C-peptide) ### Histopathology At the pancreatic level, LADA shows: - Selective insulitis (lymphocytic infiltration of islets) - Preserved exocrine pancreas - Progressive β-cell apoptosis - Fibrosis of affected islets **High-Yield:** LADA accounts for 5–10% of "Type 2 DM" cases in adults; misclassification is common. The presence of **any autoantibody** (GAD, IA2, or ZnT8) in an adult with diabetes should trigger reclassification. ### Differentiation from Type 2 DM | Feature | LADA (Autoimmune) | Type 2 DM (Insulin Resistance) | |---------|-------------------|--------------------------------| | **Age of onset** | >30 years, gradual | Any age, often insidious | | **BMI** | Usually lean | Usually overweight | | **C-peptide** | Low (<0.5 ng/mL) | Normal or elevated | | **Autoantibodies** | Positive (GAD, IA2, ZnT8) | Negative | | **Acanthosis nigricans** | Absent | Often present | | **Pathology** | β-cell destruction | Insulin resistance + β-cell dysfunction | **Clinical Pearl:** LADA patients often respond poorly to oral antidiabetic agents and require insulin therapy earlier than typical Type 2 DM patients, reflecting the underlying β-cell loss. ### Why Other Options Are Wrong Option B (insulin resistance) is ruled out by: - Lean BMI (21 kg/m²) - Absence of metabolic syndrome features - Positive autoantibodies Option C (impaired glucose sensing) would show elevated C-peptide and negative antibodies. Option D (hepatic gluconeogenesis) does not explain the positive autoantibodies or low C-peptide.